|
|
| PMID |
|
|
| TITLE |
|
| Associations Between Cannabis Use, Polygenic Liability for Schizophrenia, and Cannabis-related Experiences in a Sample of Cannabis Users. |
|
| ABSTRACT |
|
| BACKGROUND AND HYPOTHESIS |
NlmCategory: OBJECTIVE |
| Risk for cannabis use and schizophrenia is influenced in part by genetic factors, and there is evidence that genetic risk for schizophrenia is associated with subclinical psychotic-like experiences (PLEs). Few studies to date have examined whether genetic risk for schizophrenia is associated with cannabis-related PLEs. |
| STUDY DESIGN |
NlmCategory: METHODS |
| Risk for cannabis use and schizophrenia is influenced in part by genetic factors, and there is evidence that genetic risk for schizophrenia is associated with subclinical psychotic-like experiences (PLEs). Few studies to date have examined whether genetic risk for schizophrenia is associated with cannabis-related PLEs. We tested whether measures of cannabis involvement and polygenic risk scores (PRS) for schizophrenia were associated with self-reported cannabis-related experiences in a sample ascertained for alcohol use disorders (AUDs), the Collaborative Study on the Genetics of Alcoholism (COGA). We analyzed 4832 subjects (3128 of European ancestry and 1704 of African ancestry; 42% female; 74% meeting lifetime criteria for an AUD). |
| STUDY RESULTS |
NlmCategory: RESULTS |
| Risk for cannabis use and schizophrenia is influenced in part by genetic factors, and there is evidence that genetic risk for schizophrenia is associated with subclinical psychotic-like experiences (PLEs). Few studies to date have examined whether genetic risk for schizophrenia is associated with cannabis-related PLEs. We tested whether measures of cannabis involvement and polygenic risk scores (PRS) for schizophrenia were associated with self-reported cannabis-related experiences in a sample ascertained for alcohol use disorders (AUDs), the Collaborative Study on the Genetics of Alcoholism (COGA). We analyzed 4832 subjects (3128 of European ancestry and 1704 of African ancestry; 42% female; 74% meeting lifetime criteria for an AUD). Cannabis use disorder (CUD) was prevalent in this analytic sample (70%), with 40% classified as mild, 25% as moderate, and 35% as severe. Polygenic risk for schizophrenia was positively associated with cannabis-related paranoia, feeling depressed or anhedonia, social withdrawal, and cognitive difficulties, even when controlling for duration of daily cannabis use, CUD, and age at first cannabis use. The schizophrenia PRS was most robustly associated with cannabis-related cognitive difficulties (β = 0.22, SE = 0.04, P = 5.2e-7). In an independent replication sample (N = 1446), associations between the schizophrenia PRS and cannabis-related experiences were in the expected direction and not statistically different in magnitude from those in the COGA sample. |
| CONCLUSIONS |
NlmCategory: CONCLUSIONS |
| Risk for cannabis use and schizophrenia is influenced in part by genetic factors, and there is evidence that genetic risk for schizophrenia is associated with subclinical psychotic-like experiences (PLEs). Few studies to date have examined whether genetic risk for schizophrenia is associated with cannabis-related PLEs. We tested whether measures of cannabis involvement and polygenic risk scores (PRS) for schizophrenia were associated with self-reported cannabis-related experiences in a sample ascertained for alcohol use disorders (AUDs), the Collaborative Study on the Genetics of Alcoholism (COGA). We analyzed 4832 subjects (3128 of European ancestry and 1704 of African ancestry; 42% female; 74% meeting lifetime criteria for an AUD). Cannabis use disorder (CUD) was prevalent in this analytic sample (70%), with 40% classified as mild, 25% as moderate, and 35% as severe. Polygenic risk for schizophrenia was positively associated with cannabis-related paranoia, feeling depressed or anhedonia, social withdrawal, and cognitive difficulties, even when controlling for duration of daily cannabis use, CUD, and age at first cannabis use. The schizophrenia PRS was most robustly associated with cannabis-related cognitive difficulties (β = 0.22, SE = 0.04, P = 5.2e-7). In an independent replication sample (N = 1446), associations between the schizophrenia PRS and cannabis-related experiences were in the expected direction and not statistically different in magnitude from those in the COGA sample. Among individuals who regularly use cannabis, genetic liability for schizophrenia-even in those without clinical features-may increase the likelihood of reporting unusual experiences related to cannabis use. |
| © The Author(s) 2022. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. |
|
| DATE PUBLISHED |
|
|
| HISTORY |
|
| PUBSTATUS |
PUBSTATUSDATE |
| entrez |
2022/12/22 04:13 |
| pubmed |
2022/12/23 06:00 |
| medline |
2022/12/23 06:00 |
|
| AUTHORS |
|
| NAME |
COLLECTIVENAME |
LASTNAME |
FORENAME |
INITIALS |
AFFILIATION |
AFFILIATIONINFO |
| Johnson EC |
|
Johnson |
Emma C |
EC |
|
Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, USA. |
| Colbert SMC |
|
Colbert |
Sarah M C |
SMC |
|
Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, USA. |
| Jeffries PW |
|
Jeffries |
Paul W |
PW |
|
Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, USA. |
| Tillman R |
|
Tillman |
Rebecca |
R |
|
Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, USA. |
| Bigdeli TB |
|
Bigdeli |
Tim B |
TB |
|
Henri Begleiter Neurodynamics Lab, SUNY Downstate Health Sciences University, Brooklyn, NY, USA. |
| Karcher NR |
|
Karcher |
Nicole R |
NR |
|
Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, USA. |
| Chan G |
|
Chan |
Grace |
G |
|
Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, IA, USA. |
| Kuperman S |
|
Kuperman |
Samuel |
S |
|
Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, IA, USA. |
| Meyers JL |
|
Meyers |
Jacquelyn L |
JL |
|
Henri Begleiter Neurodynamics Lab, SUNY Downstate Health Sciences University, Brooklyn, NY, USA. |
| Nurnberger JI |
|
Nurnberger |
John I |
JI |
|
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA. |
| Plawecki MH |
|
Plawecki |
Martin H |
MH |
|
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA. |
| Degenhardt L |
|
Degenhardt |
Louisa |
L |
|
National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia. |
| Martin NG |
|
Martin |
Nicholas G |
NG |
|
QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. |
| Kamarajan C |
|
Kamarajan |
Chella |
C |
|
Henri Begleiter Neurodynamics Lab, SUNY Downstate Health Sciences University, Brooklyn, NY, USA. |
| Schuckit MA |
|
Schuckit |
Marc A |
MA |
|
Department of Psychiatry, University of California San Diego Medical School, San Diego, CA, USA. |
| Murray RM |
|
Murray |
Robin M |
RM |
|
Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. |
| Dick DM |
|
Dick |
Danielle M |
DM |
|
Department of Psychiatry, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. |
| Edenberg HJ |
|
Edenberg |
Howard J |
HJ |
|
Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA. |
| D'Souza DC |
|
D'Souza |
Deepak Cyril |
DC |
|
Psychiatry Service, VA Connecticut Healthcare System, West Haven, CT, USA. |
| Di Forti M |
|
Di Forti |
Marta |
M |
|
South London and Maudsley NHS Mental Health Foundation Trust, London, UK. |
| Porjesz B |
|
Porjesz |
Bernice |
B |
|
Henri Begleiter Neurodynamics Lab, SUNY Downstate Health Sciences University, Brooklyn, NY, USA. |
| Nelson EC |
|
Nelson |
Elliot C |
EC |
|
Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, USA. |
| Agrawal A |
|
Agrawal |
Arpana |
A |
|
Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, USA. |
|
| INVESTIGATORS |
|
|
| JOURNAL |
|
| VOLUME: |
| ISSUE: |
| TITLE: Schizophrenia bulletin |
| ISOABBREVIATION: Schizophr Bull |
| YEAR: 2022 |
| MONTH: Dec |
| DAY: 21 |
| MEDLINEDATE: |
| SEASON: |
| CITEDMEDIUM: Internet |
| ISSN: 1745-1701 |
| ISSNTYPE: Electronic |
|
| MEDLINE JOURNAL |
|
| MEDLINETA: Schizophr Bull |
| COUNTRY: United States |
| ISSNLINKING: 0586-7614 |
| NLMUNIQUEID: 0236760 |
|
| PUBLICATION TYPE |
|
| PUBLICATIONTYPE TEXT |
| Journal Article |
|
| COMMENTS AND CORRECTIONS |
|
|
| GRANTS |
|
| GRANTID |
AGENCY |
COUNTRY |
| R01 DA17305 |
NIDA NIH HHS |
United States |
| N01-HG-65403 |
NIH HHS |
United States |
|
| GENERAL NOTE |
|
|
| KEYWORDS |
|
|
| MESH HEADINGS |
|
|
| SUPPLEMENTARY MESH |
|
|
| GENE SYMBOLS |
|
|
| CHEMICALS |
|
|
| OTHER ID's |
|
|
|
